Sun Pharmaceutical Industries Limited — Important, 10-04-2025: General Updates

The U.S. Court of Appeals for the Federal Circuit has ruled in favor of Sun Pharmaceutical Industries Limited by vacating the preliminary injunction that previously delayed the launch of LEQSELVI™ (deuruxolitinib) in the United States. The injunction, granted by the U.S. District Court for the District of New Jersey, is now no longer in effect, allowing the company to proceed without court-imposed restrictions. Although litigation with Incyte Corporation continues, Sun Pharma will announce its launch plans for LEQSELVI™ in due course. This development represents a significant opportunity for the company's growth in the U.S. market.